Developing safe and effective gene therapies using AAV vectors is hindered by challenges related to the immune response. However, over the past two decades, drug developers have identified and are working on solutions to various immune responses to AAV vectors.
The 4th Annual Gene Therapy Immunogenicity Summit is an opportunity for gene ther
05-07 September 2023